175 related articles for article (PubMed ID: 22165909)
21. Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform.
Blackburn C; Barrett C; Chin J; Garcia K; Gigstad K; Gould A; Gutierrez J; Harrison S; Hoar K; Lynch C; Rowland RS; Tsu C; Ringeling J; Xu H
J Med Chem; 2013 Sep; 56(18):7201-11. PubMed ID: 23964961
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
[TBL] [Abstract][Full Text] [Related]
23. Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
Pabba C; Gregg BT; Kitchen DB; Chen ZJ; Judkins A
Bioorg Med Chem Lett; 2011 Jan; 21(1):324-8. PubMed ID: 21109435
[TBL] [Abstract][Full Text] [Related]
24. Deacetylase inhibitor trichostatin A down-regulates Foxp3 expression and reduces CD4+CD25+ regulatory T cells.
Liu Z; Zhang C; Sun J
Biochem Biophys Res Commun; 2010 Sep; 400(3):409-12. PubMed ID: 20801101
[TBL] [Abstract][Full Text] [Related]
25. Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
Chao SW; Chen LC; Yu CC; Liu CY; Lin TE; Guh JH; Wang CY; Chen CY; Hsu KC; Huang WJ
Eur J Med Chem; 2018 Jan; 143():792-805. PubMed ID: 29223096
[TBL] [Abstract][Full Text] [Related]
26. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
27. Carbamate prodrug concept for hydroxamate HDAC inhibitors.
Schlimme S; Hauser AT; Carafa V; Heinke R; Kannan S; Stolfa DA; Cellamare S; Carotti A; Altucci L; Jung M; Sippl W
ChemMedChem; 2011 Jul; 6(7):1193-8. PubMed ID: 21416613
[No Abstract] [Full Text] [Related]
28. Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.
De Vreese R; D'hooghe M
Eur J Med Chem; 2017 Jul; 135():174-195. PubMed ID: 28453994
[TBL] [Abstract][Full Text] [Related]
29. Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases.
Lee HY; Wang LT; Li YH; Pan SL; Chen YL; Teng CM; Liou JP
Org Biomol Chem; 2014 Nov; 12(44):8966-76. PubMed ID: 25277250
[TBL] [Abstract][Full Text] [Related]
30. [Tubacin promotes Foxp3 expression and suppressive function of mouse CD4+;CD25+; regulatory T cells].
Zhao S; Chen Z; Yu D; Tang M; Zhang W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Mar; 32(3):339-42. PubMed ID: 26927553
[TBL] [Abstract][Full Text] [Related]
31. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
[TBL] [Abstract][Full Text] [Related]
32. Potent and selective HDAC6 inhibitory activity of N-(4-hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorenes as novel sulfur analogues of Tubastatin A.
De Vreese R; Verhaeghe T; Desmet T; D'hooghe M
Chem Commun (Camb); 2013 May; 49(36):3775-7. PubMed ID: 23538448
[TBL] [Abstract][Full Text] [Related]
33. Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity.
Huong TT; Dung DT; Huan NV; Cuong LV; Hai PT; Huong LT; Kim J; Kim YG; Han SB; Nam NH
Bioorg Chem; 2017 Apr; 71():160-169. PubMed ID: 28196602
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
Liu R; Wang J; Tang W; Fang H
Bioorg Med Chem; 2016 Apr; 24(7):1446-54. PubMed ID: 26907204
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro.
Oh BR; Suh DH; Bae D; Ha N; Choi YI; Yoo HJ; Park JK; Lee EY; Lee EB; Song YW
Arthritis Res Ther; 2017 Jul; 19(1):154. PubMed ID: 28673326
[TBL] [Abstract][Full Text] [Related]
36. Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors.
Rossi C; Porcelloni M; D'Andrea P; Fincham CI; Ettorre A; Mauro S; Squarcia A; Bigioni M; Parlani M; Nardelli F; Binaschi M; Maggi CA; Fattori D
Bioorg Med Chem Lett; 2011 Apr; 21(8):2305-8. PubMed ID: 21420859
[TBL] [Abstract][Full Text] [Related]
37. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A.
Butler KV; Kalin J; Brochier C; Vistoli G; Langley B; Kozikowski AP
J Am Chem Soc; 2010 Aug; 132(31):10842-6. PubMed ID: 20614936
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease.
Pinho BR; Reis SD; Guedes-Dias P; Leitão-Rocha A; Quintas C; Valentão P; Andrade PB; Santos MM; Oliveira JM
Pharmacol Res; 2016 Jan; 103():328-39. PubMed ID: 26657418
[TBL] [Abstract][Full Text] [Related]
39. Synthesis of benzothiophene-based hydroxamic acids as potent and selective HDAC6 inhibitors.
De Vreese R; Van Steen N; Verhaeghe T; Desmet T; Bougarne N; De Bosscher K; Benoy V; Haeck W; Van Den Bosch L; D'hooghe M
Chem Commun (Camb); 2015 Jun; 51(48):9868-71. PubMed ID: 25994553
[TBL] [Abstract][Full Text] [Related]
40. Tubastatin A suppresses renal fibrosis via regulation of epigenetic histone modification and Smad3-dependent fibrotic genes.
Choi SY; Ryu Y; Kee HJ; Cho SN; Kim GR; Cho JY; Kim HS; Kim IK; Jeong MH
Vascul Pharmacol; 2015 Sep; 72():130-40. PubMed ID: 25921924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
